- Sessions, Nielsen address nation's sheriffs amid outcry over immigration -- live stream
- Disney is expected to add cash to its bid for Twenty-First Century Fox assets: Sources
- Merkel: In EU asylum policy, others have interests as well as us
- CSU leader to reject migrants at German border if no EU deal
- How to play rising interest rates based on your age
Shares of the robotic surgery company TransEnterix (NYSEMKT: TRXC) ended the day higher by a healthy 12.8%. The catalyst?
Continue Reading Below
The robotic surgery company’s shares perked up in response to a bullish note by RBC Capital analyst Glenn Novarro. Specifically, Novarro stated that the commercial launch of TransEnterix’s newly approved Senhance system should only continue to gain momentum going forward, and the system’s sales should more than double from current levels before year’s end.
TransEnterix’s stock is now up by an impressive 80.5% this month, thanks in large part to Senhance’s better-than-expected commercial launch.
When TransEnterix’s Senhance system was first approved last October, Wall Street wasn’t overly optimistic that the company could effectively compete against Intuitive Surgical‘s entrenched da vinci system. Intuitive, after all, has an 18-year head start, and robotic surgery platforms require extensive training to operate and maintain.
In other words, it wasn’t a given that conservative-minded hospital administrators would be willing to take a chance on a novel robotic surgery platform manufactured by a company with a less-than-stellar balance sheet. However, TransEnterix is so far proving the naysayers wrong, with the company already selling a whopping five units right out of the gate.
Looking ahead, TransEnterix is working toward broadening Senhance’s commercial opportunity via a label expansion that would cover both laparoscopic inguinal hernia and laparoscopic gallbladder surgeries. The U.S. Food and Drug Administration is expected to make its regulatory decision on this label expansion by midyear.
Before investors get too excited, however, it’s important to bear in mind that TransEnterix’s shares are now trading at a forward-looking price-to-sales ratio of around 17, implying that most of the stock’s near-term upside potential is already baked into the price right now. So, it’s probably not a good idea to enter at this point unless you are willing to hold the company’s shares for an extended period.
10 stocks we like better than TransEnterixWhen investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now… and TransEnterix wasn’t one of them! That’s right — they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of May 8, 2018